<DOC>
	<DOCNO>NCT00406809</DOCNO>
	<brief_summary>The Phase 1 portion study evaluate pharmacokinetic profile safety ABT-263 objective defining dose limit toxicity maximum tolerate dose subject lymphoid malignancy . The Phase 2a portion study evaluate ABT-263 use step-up dose regimen may increase define recommended Phase 2 dose obtain additional safety information preliminary assessment efficacy subject lymphoid malignancy . The Extension portion study allow Phase 2a subject remain active 1 year last subject enrolls study approximately 1 year continue receive ABT-263 le frequent study evaluation . Subjects Extension Study continue receive study drug 7 year last subject transition Extension Study , disease progression toxicity necessitate discontinuation ( whichever come first ) .</brief_summary>
	<brief_title>A Study ABT-263 Subjects With Relapsed Refractory Lymphoid Malignancies</brief_title>
	<detailed_description>Enrollment breakdown : Entered Study : Phase 1a : 39 ; Phase 1b : 19 ; Phase 2a : 33 ; Total : 91 Entered Treatment : Phase 1a : 38 ; Phase 1b : 17 ; Phase 2a : 26 ; Total : 81</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>Diagnoses : 1a/1b lymphoid malignancy ; 2a , Arm A follicular lymphoma ; 2a , Arm B mantle cell , peripheral cutaneous Tcell lymphoma include mycosis fungoides Sezary syndrome indolent Bcell lymphomas marginal zone lymphoma ; Received least 1 prior chemotherapy treatment regimen ( P1a/1b ) relapse refractory disease ( P2a ) . Eastern Cooperative Oncology Group ( ECOG ) score &lt; = 1 . Magnetic Resonance Imaging ( MRI ) /computed tomography ( CT ) negative subdural epidural hematoma w/in 28 day prior first dose , clinically indicate . Stable dose Selective serotonin reuptake inhibitor ( SSRI ) antidepressants least 21 day prior 1st dose . Adequate bone marrow ( BM ) independent growth factor support ( except heavily infiltrate bone marrow ( 80 % ) ) : Absolute Neutrophil Count ( ANC ) &gt; = 1000/µL ; Platelets &gt; = 100,000/mm3 ( entry count must independent transfusion 14 day Screening ) ; Hemoglobin &gt; = 9.0/dL . Adequate coagulation , renal , hepatic function : Serum creatinine &lt; = 2.0 mg/dL calculate creatinine clearance &gt; = 50 mL/min ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 3.0 x Upper Limit Normal ( ULN ) ; Bilirubin &lt; = 1.5 x ULN ; Gilbert 's Syndrome may bilirubin &gt; 1.5 x ULN ; Coagulation : Activated partial thromboplastin time ( aPTT ) , Prothrombin Time ( PT ) , exceed 1.2 x ULN Females must surgically sterile , postmenopausal ( least 1 year ) , negative result pregnancy test perform Screening serum sample obtain 14 day prior initial dose , prior dose urine sample obtain C1 D3 ( P1a ) Leadin D1 ( P1b , P2a ) &gt; 7 day since serum result . Females surgically sterile postmenopausal ( least 1 year ) nonvasectomized male must practice birth control . P2a : History autologous stem cell transplant must &gt; 6 month post transplant adequate BM independent growth factor support per lab reference range Screening follow : Absolute Neutrophil Count ( ANC ) &gt; = 1,500/µL ; Platelets &gt; = 125,000/mm3 ( entry platelet count must independent transfusion 14 day Screening ) ; Hemoglobin &gt; = 10.0g/dL ; Measurable disease International Working Group ( IWG ) /National Cancer Institute sponsor Working Group ( NCIWG ) criterion . At least one follow Pharmacodynamics ( P2a ) : archive diagnostic Formalin Fixed Paraffin Embedded ( FFPE ) tumor tissue intervene treatment since biopsy , core needle biopsy malignant lymph node , bone marrow aspirate core positive lymphoma . Extension Study Inclusion Criteria Phase 2a subject enter Extension Study must continue meet Inclusion Exclusion criterion , exception Inclusion Criterion regard measurable disease International Working Group ( IWG ) /National Cancer Institute sponsor Working Group ( NCIWG ) criterion Inclusion Criteria regard laboratory parameter hematology , coagulation , chemistry . Subjects enter Extension Study must also stable lab value per applicable laboratory reference range . In addition , subject must also meet follow criterion : Subjects must meet follow hematology coagulation lab criterion : Platelet count must &gt; = 25,000/mm3 ( untransfused ) . Platelet count &lt; = 50,000/mm3 must stable monitor increased frequency discretion investigator . Absolute Neutrophil count ( ANC ) &gt; = 500/µL . ANC &gt; = 500/µL &lt; 1,000/µL monitor increased frequency discretion investigator . Hemoglobin &gt; = 8.0 g/dL . aPTT , PT exceed 1.2 x ULN . Chemistry value must exceed Grade 2 . Grade 2 chemistry lab monitor increased frequency discretion investigator . Subjects must meet following chemistry criterion : Serum creatinine &lt; = 3.0 x upper normal limit ( ULN ) institution 's normal range . * AST ALT &lt; = 5.0 x upper normal limit ( ULN ) institution 's normal range . Bilirubin &lt; = 3.0 x ULN . Subjects Gilbert 's Syndrome may allow Bilirubin &gt; 3.0 x ULN base joint decision investigator Abbott medical monitor . History , , clinically suspicious cancerrelated Central Nervous System ( CNS ) disease , lymphoid nonlymphoid . Undergone allogeneic autologous stem cell transplant . Underlying , predispose condition bleed currently exhibit sign clinically significant bleeding . Recent history nonchemotherapy induce thrombocytopenic associate bleed 1 year prior first dose . Active peptic ulcer disease hemorrhagic esophagitis/gastritis . Active immune thrombocytopenic purpura history refractory platelet transfusion 1 year prior first dose . Significant history cardiovascular disease , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease . Females pregnant breastfeeding . Positive human immunodeficiency virus ( HIV ) History active malignancy past 3 year ( P1a/1b ) past 5 year ( P2a ) , except adequately treat situ carcinoma cervix uterus ; basal squamous cell carcinoma ; situ carcinoma bladder ; previous malignancy confine surgically resect curative intent . Evidence clinically significant uncontrolled condition ( ) , include , limited active systemic fungal infection ; diagnosis fever neutropenia 1 week prior study drug . Received steroid therapy 7 day prior 1st dose study drug antineoplastic intent . Received anticancer therapy , include chemotherapy , immunotherapy , radiotherapy , hormonal investigational therapy , 14 day prior first dose study drug , recover &lt; Gr2 clinically significant AE ( ) /toxicity ( ) previous therapy . Received biologic 30 day prior first dose . Currently receive require anticoagulation therapy drug herbal supplement affect platelet function , exception lowdose anticoagulation medication use maintain patency central venous catheter . Received aspirin 7 day prior first dose ABT263 administration . Consumed grapefruit grapefruit product 3 day prior first dose . P1a/1b : Diagnosed Posttransplant lymphoproliferative disorder ( PTLD ) ; Burkitt 's , Burkittlike , HIVassociate lymphoma ; lymphoblastic lymphoma/leukemia ; multiple myeloma . Subject receive CYP3A inhibitor ( e.g. , ketoconazole , clarithromycin ) within 7 day prior administration first dose ABT263 ( P2a ) . Subject prior significant toxicity another Bcl2 family protein inhibitor ( P2a ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sezary syndrome</keyword>
	<keyword>cutaneous T-cell lymphoma</keyword>
	<keyword>follicular lymphoma</keyword>
	<keyword>marginal zone lymphoma</keyword>
	<keyword>indolent T-cell lymphoma</keyword>
	<keyword>Navitoclax</keyword>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>peripheral T-cell lymphoma</keyword>
	<keyword>ABT-263</keyword>
	<keyword>lymphoid malignancy</keyword>
	<keyword>chronic lymphoid leukemia</keyword>
	<keyword>mycosis fungoides</keyword>
	<keyword>mantle cell lymphoma</keyword>
</DOC>